相似文献
1
Perspectives and opportunities for nanomedicine in the management of atherosclerosis.
Nat Rev Drug Discov. 2011 Oct 21;10(11):835-52. doi: 10.1038/nrd3578.
2
Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
Arch Pharm Res. 2018 Feb;41(2):111-129. doi: 10.1007/s12272-017-0995-x. Epub 2017 Dec 6.
3
Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
Int J Mol Sci. 2014 Mar 4;15(3):3904-25. doi: 10.3390/ijms15033904.
4
Nanomedicine-based strategies for treatment of atherosclerosis.
Trends Mol Med. 2014 May;20(5):271-81. doi: 10.1016/j.molmed.2013.12.001. Epub 2014 Mar 1.
5
Nanomedicine--prospective therapeutic and diagnostic applications.
Expert Opin Biol Ther. 2005 Jan;5(1):1-5. doi: 10.1517/14712598.5.1.1.
6
Targeting and therapeutic peptides in nanomedicine for atherosclerosis.
Exp Biol Med (Maywood). 2016 May;241(9):891-8. doi: 10.1177/1535370216640940. Epub 2016 Mar 27.
7
Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Pharmacol Ther. 2010 Nov;128(2):324-35. doi: 10.1016/j.pharmthera.2010.07.007. Epub 2010 Aug 10.
8
The emerging applications of magnetic nanovectors in nanomedicine.
Pharm Pat Anal. 2015;4(4):285-304. doi: 10.4155/ppa.15.17.
9
The upcoming field of theranostic nanomedicine: an overview.
J Biomed Nanotechnol. 2012 Dec;8(6):859-82. doi: 10.1166/jbn.2012.1459.
10
Nanomedicine for the prevention, treatment and imaging of atherosclerosis.
Nanomedicine. 2012 Sep;8 Suppl 1:S59-68. doi: 10.1016/j.nano.2012.05.006. Epub 2012 May 26.
引用本文的文献
1
A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis.
Nat Commun. 2025 Jul 11;16(1):6445. doi: 10.1038/s41467-025-61789-9.
2
SERS and colorimetric dual-mode detection of cholesterol during drug treatment of atherosclerosis.
Anal Bioanal Chem. 2025 May 22. doi: 10.1007/s00216-025-05910-3.
3
Key parameters for designing robust 2D and 3D spheroid models for atherosclerosis research.
Bioeng Transl Med. 2025 Mar 21;10(3):e10736. doi: 10.1002/btm2.10736. eCollection 2025 May.
4
Recent progress in ROS-responsive biomaterials for the diagnosis and treatment of cardiovascular diseases.
Theranostics. 2025 Apr 11;15(11):5172-5219. doi: 10.7150/thno.106991. eCollection 2025.
5
High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy.
Polymers (Basel). 2025 Feb 26;17(5):625. doi: 10.3390/polym17050625.
6
Single chain fragment variable, a new theranostic approach for cardiovascular diseases.
Front Immunol. 2024 Dec 13;15:1443290. doi: 10.3389/fimmu.2024.1443290. eCollection 2024.
7
Lipoic Acid Nanoparticles Exert Effective Antiatherosclerosis Effects through Anti-Inflammatory and Antioxidant Pathways.
ACS Omega. 2024 Nov 25;9(49):48642-48649. doi: 10.1021/acsomega.4c07745. eCollection 2024 Dec 10.
8
Nanomaterials for stroke diagnosis and treatment.
iScience. 2024 Oct 9;27(11):111112. doi: 10.1016/j.isci.2024.111112. eCollection 2024 Nov 15.
9
Nanomedicine-based strategies for the treatment of vein graft disease.
Nat Rev Cardiol. 2025 Apr;22(4):255-272. doi: 10.1038/s41569-024-01094-y. Epub 2024 Nov 5.
10
Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.
Pharmaceutics. 2024 Aug 3;16(8):1037. doi: 10.3390/pharmaceutics16081037.
本文引用的文献
1
Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy.
Acc Chem Res. 2011 Oct 18;44(10):842-52. doi: 10.1021/ar200084x. Epub 2011 Jun 10.
2
Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.
J Thromb Haemost. 2011 Jul;9(7):1292-300. doi: 10.1111/j.1538-7836.2011.04339.x.
3
Progress and challenges in translating the biology of atherosclerosis.
Nature. 2011 May 19;473(7347):317-25. doi: 10.1038/nature10146.
4
Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging.
Circulation. 2011 May 17;123(19):2157-63. doi: 10.1161/CIRCULATIONAHA.110.000943.
5
Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis.
JACC Cardiovasc Imaging. 2011 May;4(5):537-48. doi: 10.1016/j.jcmg.2011.03.006.
6
Anti-inflammatory therapeutics for the treatment of atherosclerosis.
Nat Rev Drug Discov. 2011 May;10(5):365-76. doi: 10.1038/nrd3444.
7
Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial.
Am J Med. 2011 May;124(5):434-43. doi: 10.1016/j.amjmed.2010.11.027.
8
Microfabrication and nanotechnology in stent design.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 May-Jun;3(3):256-68. doi: 10.1002/wnan.123. Epub 2011 Jan 31.
9
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.
Nat Cell Biol. 2011 Apr;13(4):423-33. doi: 10.1038/ncb2210. Epub 2011 Mar 20.
10
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.
J Am Coll Cardiol. 2011 Mar 15;57(11):1314-22. doi: 10.1016/j.jacc.2011.01.011.
Zotero 插件